Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma
Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and
cisplatin followed by high dose chemotherapy with treosulfan, etoposide and cisplatin (TEC)
an autologous peripheral blood stem cell transplantation(aPBSCT). In case of only partial
remission a second identical high dose chemotherapy and aPBSCT follows. Patients with
primary refractory disease or early relapse within 6 months should receive a allogenous stem
cell transplantation. For Patients with CD 20 positive B-cell lymphoma the chemotherapy
regiments DHAP and TEC are combined with rituximab.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Michael Koenigsmann, PD Dr. med.
University of Magdeburg
Germany: Ethics Commission